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ABSTRACT
The pharmacokinetics of cefepime after its single intravenous administration (10 mg/kg) was 
investigated in experimentally induced fever in buffalo calves (n = 4). The fever was induced by single/
repeated intravenous injection of E. coli lipopolysaccaride (1 μg/kg). The drug was estimated in plasma samples 
by microbiological assay using E. coli (MTCC 739) test organism. The pharmacokinetic behaviour of cefepime 
in febrile animals was described by a two compartment open model. At 1 min, the concentration of cefepime 
in plasma was 40.8 ± 0.98 μg/mL which rapidly declined to 23.0 ± 0.64 μg/mL at 15 min. The drug 
was detected up to 24 h. The elimination half-life and volume of distribution were 3.00 ± 0.18 h and 
0.42 ± 0.02 L/kg, respectively. The distribution half-life, AUC and total body clearance (ClB) were 
0.08 ± 0.002 h, 101 ± 7.65 μg/mL.h and 98.8 ± 6.06 mL/kg/h, respectively. To maintain a minimum 
therapeutic concentration of 1 μg/mL, a satisfactory dosage regimen of cefepime in febrile buffalo calves would 
be 7 mg/kg repeated at 12 h intervals.
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 Introduction
Cefepime, is a parenteral semisynthetic bactericidal cephalosporin having 
excellent activity against a broad spectrum of clinically important pathogens, including 
Staphylococcus aureus and Pseudomonas aeruginosa strains resistant to other 
broad spectrum cephalosporins (BARBHAIYA et al., 1992). The pharmacokinetics of 
chemotherapeutic agents are markedly altered in disease conditions (LESAR and ZASKE 
1984; HARY et al., 1989; TOTH et al., 1991; SINGH et al., 1998; CHAUDHARY et al., 1999; 
DARDI et al., 2005; SHARMA et al., 2005), hence the dosage regimen obtained in healthy 
subjects cannot be always extrapolated in clinical cases to treat diseased animals. Fever, 
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which is one of the most common manifestations of many infectious diseases, is reported 
to induce a series of biochemical and physiological alterations in cells (MONSHOUWER 
et al., 1996). So, a study of the infl uence of fever on the pharmacokinetics of antibiotics 
is essential. The purpose of this study was to determine the pharmacokinetic variables 
of cefepime in febrile buffalo calves following intravenous administration. From the 
pharmacokinetic data, recommendations were made for the optimal dosage regimen of 
cefepime in febrile buffalo calves. 
Materials and methods
The experiment was performed on four male buffalo calves, 6-10 months of age and 
weighing an average of 91 kg. The animals were housed in a departmental shed with a 
concrete fl oor and were provided green fodder and water ad libitum. Each animal was 
quarantined for three weeks before the start of the experiment and was determined to be 
healthy by regular clinical examination. Fever was induced by single/repeated intravenous 
administration of E. coli lipopolysaccaride (LPS) at the dose rate of 1μg/kg body mass 
(DARDI et al., 2005). Once fever was induced (1-2 h after LPS injection) cefepime was 
injected intravenously to these four animals at a dose rate of 10 mg/kg of cefepime, in a 
10% solution with sterilized distilled water. Blood samples (4-5 mL each) were withdrawn 
from the contralateral jugular vein into heparanized glass test tubes before administration 
and at 1, 2.5, 5, 7.5, 10, 15, 30, 45 and 60 minutes and 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 h 
after administration of the drug. Plasma was collected after centrifugation at 2000g for 15 
minutes at room temperature and kept at -200 C until analysis, usually the next day. The 
concentration of cefepime in plasma was estimated by employing the microbiological 
assay technique (ARRET et al., 1971) using Escherichia coli (MTCC 739) as the test 
organism. The bioassay method used in this work could not distinguish between the parent 
compound and its active metabolites. However, it measured the overall microbiological 
activity of the drug. The standard curve of cefepime equivalent in buffalo calf plasma was 
linear between 0.25 to 1.25 μg/mL. The drug could be detected up to a minimum limit of 
0.1 μg/mL. The intra day and inter day coeffi cient of variance was 4.2 and 9.39 per cent, 
respectively. The plasma concentration-time data for each buffalo calf were determined 
according to the computed least squares regression technique. The kinetic parameters 
were calculated from the formulae derived for a two- compartment open model (NOTARI, 
1980; GIBALDI and PERRIER, 1982).  
The dosage regimen of cefepime was also determined based on the kinetic data. The 
priming (D) and maintenance (D1) doses are calculated from the equation:
D = Cp(min )
α.Vd e 
βτ
D1 = Cp (min)
α.Vd(e
βτ-1)
Where Cp(min) is the minimum therapeutic concentration of cefepime, τ is the dosage 
interval and other parameters are defi ned in Table 1.
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Results 
The effect of E. coli lipopolysaccharide on body temperature was recorded. The 
normal temperature in the buffalo calves was in the range of 37.1-37.6 ºC. In one animal, 
there was a significant rise in body temperature within 2 h of administration 
of lipopolysaccharide, while in three animals, the dose of lipopolysaccharide 
was repeated to obtain an optimum increase in body temperature. This dose of 
lipopolysaccaride caused fever within two hours and fever persisted for 7-10 hours. At 
least a 1.1 ºC increase of temperature from the normal temperature was taken as the time 
of cefepime administration. 
P red ic ted  concen tra tion
O bserved  concen tra tion
Fig. 1. A semi logarithmic plot of predicted and observed plasma levels of cefepime after a single 
intravenous dose of 10 mg/kg body mass in febrile buffalo calves. Values given are mean ± SE of 
four animals.
The mean plasma concentrations of cefepime as a function of time in the febrile 
buffalo calves were plotted on a semilogarithmic scale (Fig. 1). At 1 minute the mean 
plasma concentration of cefepime was 40.8 ± 0.98 μg/mL, which rapidly declined to 
plasma concentration of 23.0 ± 0.64 μg/mL at 15 minutes. Then levels gradually decreased 
to 0.29 ± 0.01 μg/mL at 24 hours. The elimination half life (t1/2β), volume of distribution 
(Vd(area)) and total body clearance in febrile animals were 3.00 ± 0.18 h, 0.42 ± 0.02 L/kg 
and 98.8 ± 6.06 mL/kg/h, respectively. Various pharmacokinetic parameters for cefepime 
in buffalo calves, in which fever was induced before administration of the drug, are given 
in Table 1. 
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Table1. Pharmacokinetic parameters of cefepime in febrile buffalo calves (n = 4) after a single 
intravenous injection of 10 mg/kg body mass 
Parametera Unit Mean ± SE
Cp
o μg/mL 44.9 ± 1.49
A μg/mL 25.3 ± 1.70
B μg/mL 19.6 ± 0.84
α h-1 8.35 ± 0.29
β h-1 0.234 ± 0.015
t1/2α h 0.08 ± 0.002
t1/2β h 3.00 ± 0.18
K12 h
-1 4.36 ± 0.28
K21 h
-1 3.77 ± 0.20
K12/K21 ratio - 1.17 ± 0.11
AUC μg/mL.h 101.0 ± 7.65
Vd(area ) L/kg 0.42 ± 0.02
Vd(SS) L/kg 0.48 ± 0.02
ClB mL/kg/h 98.8 ± 6.06
a Kinetic parameters as described by Gibaldi and Perrier (1982). Cp
o = Intercept of the back extrapolated 
concentration time curve on the concentration axis; A, B = zero-time plasma drug concentration intercepts of 
regression lines of distribution and elimination phases, respectively; α and β = distribution and elimination rate 
constants, respectively; t1/2α = distribution half life; t1/2β = elimination half life; K12, K21 = rate of transfer of drug 
from central (blood) to peripheral (tissues) compartment  and vice-versa; AUC = total area under plasma drug 
concentration-time curve; Vd(area) = apparent volume of distribution, based on area under curve; Vd(ss) = apparent 
volume of distribution, based on steady state plasma levels; ClB =  total plasma clearance.
Discussion
Evaluation of the results of plasma cefepime levels against time indicated that the 
pharmacokinetics of cefepime in febrile buffalo calves, after intravenous administration, 
was best described by the two-compartment open model. The plasma concentration-time 
data were adequately described by the equation: 
C p = Ae
-αt + Be-βt 
where Cp is cefepime concentration in plasma at time‘t’. A and B are zero time 
intercepts of the distribution and elimination phase of the plasma concentration time curve. 
α and β are the distribution and elimination rate constants, respectively, and ‘e’ represents 
the base of the natural logarithm. The disposition of cefepime, following intravenous 
injection, has been reported to follow the 2-compartment open model in calves (ISMAIL, 
2005a; PAWAR and SHARMA, 2008) and ewes (ISMAIL, 2005b), horses (GUGLICK et al., 
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1998; GARDNER and PAPICH, 2001) buffalo calves (JOSHI and SHARMA, 2007) and dogs 
(NAKANOMYO et al., 1992).
A comparison of plasma levels of cefepime in febrile animals with healthy animals 
(JOSHI and SHARMA, 2007), indicated that the peak plasma levels of cefepime in febrile 
buffalo calves (40.8 ± 0.98 μg/mL) was almost identical to healthy buffalo calves (42.7 ± 
1.85 μg/mL ). The high values of the distribution rate constant α (8.35 ± 0.29 h-1) indicates 
that cefepime is rapidly distributed into various body fl uids and tissue compartments. The 
rapid distribution of cefepime is further substantiated by high values of K12/K 21 (1.17 ± 
0.11). The elimination half-life of cefepime in febrile animals (3.00 ± 0.18 h) is similar to 
that reported in healthy animals, but longer than the values reported in other species. The 
elimination half-life of cefepime had been reported as 2.67 ± 0.29 h in healthy buffalo 
calves (JOSHI and SHARMA, 2007), 2.38 h in calves (ISMAIL, 2005a), 1.76 h in ewes 
(ISMAIL, 2005b), 2.1 h in horses (GUGLICK et al., 1998), 2 h in humans (KIEFT et al., 
1993), 1.65 h in foals and 1.09 h in dogs (GARDNER and PAPICH, 2001). The calculated 
value of volume of distribution (Vd(area)) in febrile buffalo calves (0.42 ± 0.02 L/kg) is 
more than the reported value of Vd(area) (0.225 L/kg) in horses (GUGLICK et al., 1998). 
The value of Vd(area) in buffalo calves suggested that cefepime is distributed principally 
through extracellular fl uid space. Despite low Vd(area) values for cefepime in most species, 
its effi cacy against infections located in barrier restricted compartments, such as the CNS, 
has been documented (GRASSI and GRASSI, 1993). Apparently, the low degree of plasma 
protein binding and the probable decrease in integrity of the blood brain barrier caused 
by infl ammation promote the attainment of therapeutic concentrations of cefepime in the 
brain tissue (GUGLICK et al., 1998). The value of Vd(ss) in buffalo calves (0.48 ± 0.02 L/kg) 
also indicated good extravascular distribution of the drug. As with other cephalosporins, 
the extravascular distribution of cefepime was limited to the extracellular fl uid (BALANT 
et al., 1985). In spite of its limited distribution into the extracellular fl uid, as reported in 
most species studied, it appears that low protein binding and high bacterial activity are 
considered the major determinants for promotion of its therapeutic effi cacy in all species 
(KALMAN et al., 1992). 
While comparing the total body clearance in febrile animals with that of healthy 
animals (JOSHI and SHARMA, 2007), it was found that the value of ClB in febrile animals 
(98.8 ± 6.06 mL/kg/h) is almost identical to that of healthy animals (86.1 ± 3.65 mL/kg/
h). Endotoxin causes hepatic and renal dysfunction (WILKINSON, 1977) as well 
as hemodynamic depression (VAN MIERT, 1973). Due to significant alterations in 
hepatic function, the levels of various enzymes, responsible for the metabolism of 
these antimicrobials, is altered, changing the elimination and biotransformation 
pattern of the drug during fever (SINGH et al., 1997). Cefepime is not significantly 
metabolized, but is excreted unchanged, primarily in urine by the glomerular 
filteration process, and is poorly bound to plasma proteins (BARBHAIYA et al., 
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1992), and these may be the reasons why febrile conditions did not affect the 
pharmacokinetics of cefepime. 
The ultimate objective of the present study was to determine a satisfactory dosage 
regimen in febrile buffalo calves. It is not axiomatic to be able to compute the dosage 
regimen of cefepime to be used effectively in clinical practice for the treatment of mild 
to severe bacterial infections, without having fi rst conducted a detailed pharmacokinetic 
study. With a minimum therapeutic plasma concentration of cefepime as 1.0 μg/mL 
(KNUDSEN et al., 1997) which has been shown to be most effective against the majority 
of sensitive Gram-positive and Gram-negative pathogens, the convenient and suitable 
dosage regimen of cefepime in the febrile buffalo calves after intravenous administration 
would be 7 mg/kg, repeated at 12h intervals. The dosage schedule of cefepime reported 
in healthy buffalo calves (JOSHI and SHARMA, 2007) and febrile calves (PAWAR and 
SHARMA, 2008) was 8 mg/kg, repeated at 12h and 8.2 mg/kg repeated at 8h, 
respectively. Antibiotic dosing regimens have traditionally been determined by 
pharmacokinetic parameters only. However, pharmacodynamics play an equal role, 
because pharmacodynamic parameters may be used to design dosing regimens, which 
counteract or prevent resistance. Integrating the pharmacokinetic parameters with the 
MIC gives pharmacokinetic/pharmacodynamic (PK/PD) parameters (T>MIC, Cmax/
MIC, AUC/MIC), which quantify the activity of an antibiotic. The pattern of activity 
for cephalosporins is time dependent killing and minimal persistent effects. The ideal 
dosing regimen for these antibiotics maximizes the duration of exposure. The T>MIC is 
the parameter that best correlates with effi cacy. For these drugs, maximum killing is seen 
when the time above MIC is at least 70 per cent of the dosing internal (HYATT et al., 1995). 
The T>MIC values (10 h) of cefepime suggested that this agent is clinically effective in 
the treatment of various infections manifested with fever.
References
ARRET, B., D. P. JOHNSON, A. KRISHBAUM (1971): Outline of details for microbiological 
assay of antibiotics. J. Pharma. Sci. 60, 1689-1694.
BALANT, L., P. DAYER, R. AUCKENTHALER (1985): Clinical pharmacokinetics of the third 
generation cephalosporins. Clin. Pharmacokinet. 10, 101-143.
BARBHAIYA, R. H., C. A. KNUPP, M. PFEFFER, K. A. PITTMAN (1992): Lack of 
pharmacokinetic interaction between cefepime and amikacin in humans. Antimicrob. Agents 
Chemother. 36, 1382-1386.
CHAUDHARY, R. K., A. K. SRIVASTAVA, S. RAMPAL (1999): Modifi cation of the 
pharmacokinetics and dosage of cefuroxime by endotoxin-induced fever in buffalo calves. 
Vet. Res. Commun. 23, 361-368. 
DARDI, M. S., S. K. SHARMA, A. K. SRIVASTAVA (2005). Pharmacokinetics and dosage 
regimen of ceftriaxone in E. coli lipopolysaccharide induced fever in buffalo calves. J. Vet. 
Sci. 6, 147-150.
B. Joshi and S. K. Sharma: The pharmacokinetics of cefepime in E. coli lipopolysaccharide induced febrile 
buffalo calves
529
GARDNER, S. Y., M. G. PAPICH (2001): Comparison of cefepime pharmacokinetics in neonatal 
foals and adult dogs. J. Vet. Pharmacol. Therap. 24, 187-192. 
GIBALDI, M., D. PERRIER (1982): Pharmacokinetics. Marcel and Dekker Inc., New York.
GRASSI, G. G., C. GRASSI (1993): Cefepime: overview of activity in vitro and in vivo. J. 
Antimicrob. Chemother. 32, B87-B94.
GUGLICK, M. A., C. G. MACALLISTER, C. R. CLARKE, R. POLLET, C. HAGUE, J. M. 
CLARKE (1998): Pharmacokinetics of cefepime and comparison with those of ceftiofur in 
horses. Am. J. Vet. Res. 59, 458-463. 
HARY, L., M. ANDREJAK, S. LELEU, J. ORFILA, J. P. CAPRON (1989): The pharmacokinetics 
of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Euro. J. Clin. Pharmacol. 36, 
613-616.
HYATT, J. M., P. S. MCKINNON, G. S. ZIMMER, J. J. SCHENTAG (1995): The importance of 
pharmacokinetic pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. 28, 
143-160.
ISMAIL, M. M. (2005a): Disposition kinetics, bioavailability and renal clearance of cefepime in 
calves. Vet. Res. Commun. 29, 69-79.
ISMAIL, M. M. (2005b): Pharmacokinetics of cefepime administered by i.v. and i.m. routes to 
ewes. J. Vet. Pharmacol. Therap. 28, 499-503.
JOSHI, B., S. K. SHARMA (2007): Pharmacokinetic disposition and bioavailability of cefepime in 
buffalo calves. J. Vet. Pharmacol. Therap. 30, 500-502.
KALMAN, D., S. L. BARRIERE, B. L. JOHNSON (1992): Pharmacokinetics disposition and 
bactericidal activities of cefepime, ceftazidime and cefoperazone in serum and blister fl uid. 
Antimicrob. Agents Chemother. 36, 453-457.
KIEFT, H., A. I. HOEPELMAN, C. A. KNUPP, D. A. VAN, J. M. BRANGER, B. A. STRUYVEN, 
J. L. VERHOEF (1993): Pharmacokinetics of cefepime in patients with sepsis syndrome. 
Antimicrob. Agents Chemother. 32, 117-122. 
KNUDSEN, J. D., K. FUURSTED, N. F. MOLLER, F. ESPERSEN (1997): Comparison of the effect 
of cefepime with four cephalosporins against pneumoncocci with various susceptibilities to 
penicillin, in vitro and in the mouse peritonitis model. J. Antimicrob. Chemother. 40, 679-686. 
LESAR, T. S., D. E. ZASKE (1984): Modifying dosage regimen in renal and hepatic failure. In: 
Antimicrobial Therapy. (Ristuccia A. M., B. A. Cunha, Eds). Raven Press. New York. pp. 95-
112.
MONSHOUWER, M., R. F. WITKAMP, S. M. NIJMEIJER, L. A. VANLEENGOOD, H. C. 
VERNOOY, J. H. VERHEIJDEN, A. S. J. P. A. M. VAN MIERT (1996): A lipopolysaccharide-
induced acute phase response in the pig is associated with a decrease in hepatic cytochrome 
P450-mediated drug metabolism. J. Vet. Pharmacol. Therap. 19, 382-388.
Vet. arhiv 79 (6), 523-530, 2009
B. Joshi and S. K. Sharma: The pharmacokinetics of cefepime in E. coli lipopolysaccharide induced febrile 
buffalo calves
530
NAKANOMYO, H., Y. ESUMI, M. TAKAICHI, H. SEKI, S. NINOMIYA, Y. OKAMURA, Y. 
SUDO (1992): Study on the pharmacokinetics of cefepime (II). Japanese J. Antibiot. 45, 
938-942.
NOTARI, R. E. (1980): Principle of pharmacokinetics. In: Biopharmaceutics and Clinical 
Pharmacokinetics. Marcell Dekker Inc. New York. pp 45-106. 
PAWAR, Y. G., S. K. SHARMA (2008): Infl uence of E.coli. lipopolysaccharide induced fever on 
the plasma kinetics of cefepime in cross-bred calves. Vet. Res. Commun. 32, 123-130.
SHARMA, S. K., A. K. SRIVASTAVA, M. D. DEORE (2005): Pharmacokinetics of cefotaxime in 
hepatic-dysfunctioned buffalo calves. Vet. Arhiv 75, 339-348.
SINGH, R. P., A. K. SRIVASTAVA, S. K. SHARMA, D. C. NAURIYAL (1997): Disposition 
kinetics,urinary excretion and dosage regimen of sulfadimidine in febrile crossbred calves. 
Indian J. Anim. Sci. 67, 866-867.
SINGH, R. P., A. K. SRIVASTAVA, S. K. SHARMA, D. C. NAURIYAL (1998): Infl uence of 
Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of 
oxytetracycline in crossbred calves. Acta Vet. Hung. 46, 95-100. 
TOTH, A. H., Y. ABDALLAH, R. VENKATARAMANAN, L. TEPERMAN, G. HALSF, M. 
RABINOVITCH, G. J. BURCKART, T. E. STARZ (1991): Pharmacokinetics of ceftriaxone 
in liver-transplant recipients. J. Clin. Pharmacol. 31, 722-728.
VAN MIERT, A. S. J. P. A. M. (1973): Clinical symptoms induced by E. coli endotoxin in goats. J. 
Vet. Med. A 20, 614-623.
WILKINSON, S. P. (1977): Endotoxins and liver diseases. Scand. J. Gastroenterol. 12, 385-386.
JOSHI, B., S. K. SHARMA: Farmakokinetika cefepima u bivolske teladi s vrućicom 
izazvanom lipopolisaharidom bakterije E. coli. Vet. arhiv 79, 523-530, 2009.
SAŽETAK
Istražena je farmakokinetika cefepima u bivolske teladi (n = 4) s pokusno izazvanom vrućicom nakon 
njegove jednokratne intravenske primjene (10 mg/kg). Vrućica je bila izazvana jednokratnom ili ponovljenom 
intravenskom primjenom lipopolisaharida bakterije E. coli (1 μg/kg). Farmakokinetika lijeka određivana je u 
uzorcima plazme mikrobiološkim postupkom upotrebom soja E. coli (MTCC 739).   Farmakokinetičko ponašanje 
cefepima u febrilnih životinja opisano je na osnovi dva otvorena modela. U prvoj minuti koncentracija cefepima 
u plazmi iznosila je 40,8 ± 0,98 μg/mL, a u 15. se naglo smanjila na 23,0 ± 0,64 μg/mL. Lijek je bio dokazan 
do 24 sata nakon davanja. Poluvrijeme njegova izlučivanja iznosilo je 3,00 ± 0,18 h, a količina raspodjele 0,42 
± 0,02  L/kg. Poluvrijeme njegove raspodjele iznosilo je 0,08 ± 0,002 h, površine ispod koncentracijske krivulje 
u plazmi 101 ± 7.65 μg/mL, a ukupni klirens iz organizma (ClB) 98,8 ± 6,06 mL/kg/h. Za održavanje minimalne 
terapijske koncentracije od 1 μg/mL cefepim bi u febrilne bivolske teladi trebalo davati u dozi od 7 mg/kg s 
ponovljenom primjenom u razmaku od 12 sati. 
Ključne riječi: bivolska telad, cefepim, doziranje, vrućica, farmakokinetika 
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